Contrasting Entera Bio (ENTX) & Its Competitors

Entera Bio (NASDAQ:ENTX) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Entera Bio to related businesses based on the strength of its institutional ownership, earnings, profitability, risk, valuation, analyst recommendations and dividends.

Profitability

This table compares Entera Bio and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-147.19%	-103.22%
Entera Bio Competitors	-9,046.59%	-199.78%	-30.61%

Volatility and Risk

Entera Bio has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, Entera Bio’s peers have a beta of 1.12, indicating that their average stock price is 12% more volatile than the S&P 500.

Insider & Institutional Ownership

14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 3.7% of Entera Bio shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for Entera Bio and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1	0	4	1	2.83
Entera Bio Competitors	9828	15119	45430	1586	2.54

Entera Bio presently has a consensus price target of $9.60, suggesting a potential upside of 205.73%. As a group, “Biotechnology” companies have a potential upside of 102.60%. Given Entera Bio’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Entera Bio is more favorable than its peers.

Earnings & Valuation

This table compares Entera Bio and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Entera Bio	$40,000.00	-$11.44 million	-8.97
Entera Bio Competitors	$691.14 million	$10.43 million	-15.00

Entera Bio’s peers have higher revenue and earnings than Entera Bio. Entera Bio is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Entera Bio beats its peers on 8 of the 13 factors compared.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.